Hutchmed (China) News

Ping An Securities: Maintaining the “Recommended” Rating of Hewang Pharmaceutical (00013.HK), 2023 results are in line with expectations

Zhitong FinanceApr 9 16:52

Hutchison Pharmaceutical (0013.HK): 23-year performance is in line with expectations, intensive catalysis in the global innovation pipeline

平安證券Apr 9 16:16

Hehuang Pharmaceutical (0013.HK): Major Indications Approved and Expected to Continue to Catalyze Fruquintinib's Entry into the Blue Ocean of Gastric Cancer

平安證券Apr 7 13:01

Hewang Pharmaceutical (00013.HK): Small Molecule Drug Pioneers Turn Losses into Profit Turning Point

廣發證券Mar 26 00:00

Bank Rating | Lyon: Raising BeiGene's Target Price to HK$138.5, Reiterating the “Buy” Rating

Gelonghui FinanceMar 18 10:52

Dongwu Securities: Maintaining Hewang Pharmaceutical's (00013) “buy” rating, and sevolitinib is expected to be listed in the US this year

Zhitong FinanceMar 5 09:09

Hutchison Pharmaceutical (0013.HK): Performance is in line with expectations, sales are expected to grow steadily

德邦證券Mar 5 07:26

Huhuang Pharmaceutical (0013.HK): Fruquintinib successfully marketed in the US, and sevotinib will submit an NDA as soon as the end of 2024

海通國際Mar 4 15:56

Hehuang Pharmaceutical (0013.HK): Fruquintinib dosage can be expected to soon go overseas

國泰君安Mar 1 18:26

HUTCHMED(13.HK):A FRUITFUL 2024 ON THE WAY

招银国际Mar 1 13:41

Hutchison Pharmaceutical (0013.HK): Performance is in line with expectations, and the US NDA for Savolitinib

西南證券Mar 1 00:00

Hehuang Pharmaceutical (00013.HK): Steady growth in sales and rapid overseas release of fruquintinib

華創證券Mar 1 00:00

HUTCHMED Hold Rating: Cautious Optimism Amidst Stable Outlook and International Growth Potential

TipRanksFeb 29 05:55

Hehuang Pharmaceutical (00013.HK): Fruquintinib in the US has begun to focus on clinical progress in the core pipeline

中金公司Feb 29 00:00

Hehuang Pharmaceutical (00013.HK): SYK inhibitors, pioneers of small-molecule targeted drugs, are expected to be approved within the year

浦銀國際Feb 23 00:00

Maintaining Hold on HUTCHMED: Mixed FRUTIGA Results and Fair Valuation Limit Upside

TipRanksFeb 7 12:36

Hehuang Pharmaceutical (0013.HK): FRUTIGA research data shows that fruquintinib has a high probability of being approved for second-line gastric cancer

西南證券Feb 7 00:00

Huhuang Pharmaceutical (00013.HK) Dynamic Review: Fruquintinib Global Approval Process Smooth, US Sales Volume

東北證券Feb 2 00:00

Hehuang Pharmaceutical (00013.HK): Solepinib's fourth self-developed innovative drug is expected to be approved within the year

華創證券Jan 16 12:46

Hehuang Pharmaceutical (0013.HK): Solepinib's marketing application accepted, BIC varieties highlight potential to go overseas

西南證券Jan 14 00:00